• 제목/요약/키워드: Risperidone

검색결과 57건 처리시간 0.025초

항정신병 약물과 혈당조절이상 (Antipsychotics and Abnormality in Glucose Regulation)

  • 황재승;김현;권영준;정희연
    • 생물정신의학
    • /
    • 제10권2호
    • /
    • pp.107-115
    • /
    • 2003
  • Objective:The purpose of this study was to know about the mechanism of pathogenesis of type 2 diabetes mellitus by using of blood glucose, glucoregulatory factor, insulin resistance in schizophrenic patients receiving antipsychotics. Method:Modified oral glucose tolerance tests were performed in 20 schizophrenic patients receiving haloperidol, risperidone and olanzapine. Insulin, glucagon, C-peptide and cortisol were measured in 0, 15, 45, 75 minutes after glucose loading, and insulin resistance was calculated by HOMA(homeostasis model assessment) method. Result:Olanzapine-treated patients had significant glucose elevation 45 minutes after glucose challenge. Also modest increases in HOMA IR values were detected in patients treated with olanzapine. Conclusion:Olanzapine treatment of non-diabetic patients with schizophrenia can be associated with type 2 diabetes mellitus through the elevation of glucose and insulin resistance. Elevated insulin resistance may be a causative mechanism of type 2 diabetes mellitus in patients receiving olanzapine.

  • PDF

소아청소년 양극성장애 입원 환자의 약물 사용 특성 : 후향적 차트 분석 연구 (Prescribing Patterns for Treatment of Pediatric Bipolar Disorder in a Korean Inpatient Sample)

  • 권오향;박수빈;이수민;김재원;신민섭;유희정;조수철;김붕년
    • Journal of the Korean Academy of Child and Adolescent Psychiatry
    • /
    • 제25권1호
    • /
    • pp.14-19
    • /
    • 2014
  • Objectives : This study was conducted in order to describe prescribing practices in treatment of pediatric bipolar disorder in a Korean inpatient sample. Methods : We performed a retrospective chart review of 66 youths who had been hospitalized and diagnosed with bipolar disorder according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria. Demographics, clinical characteristics, medications used, doses, and related adverse events were examined. Results : Mood stabilizers and/or atypical antipsychotic medications were the primary treatment. Risperidone, valproate, and lithium were the most commonly used. Thirty seven patients (58.1%) were treated with combination therapy of an atypical antipsychotic and mood stabilizer for improvement of manic/mixed symptoms. Conclusion : Combination pharmacotherapy was necessary for most patients in this admission sample group. Conduct of further studies will be needed for evaluation of treatment response according to the clinical characteristics, and the safety and efficacy of treatment for child and adolescent bipolar disorder.

전반적 발달장애의 한국형 치료 권고안 : 약물치료 (The Korean Practice Parameter for the Treatment of Pervasive Developmental Disorders : Pharmacological Treatment)

  • 조인희;유한익;손정우;유희정;구영진;정운선;안동현;안정숙
    • Journal of the Korean Academy of Child and Adolescent Psychiatry
    • /
    • 제18권2호
    • /
    • pp.109-116
    • /
    • 2007
  • The objective of this review is to establish practice parameters for pharmacological treatment of children and adolescents with pervasive developmental disorders. We performed a detailed review of the literature, including a wide range of controlled clinical trials, open trials, case reports, and side-effect profiles of related drugs. Few medications have a treatment indication for pervasive developmental disorders, and few studies with well-controlled methodology are available for evaluating treatment results. Pharmacological treatments focus on associated target symptoms because symptom reduction may improve educational and social ability and enhance quality of life. Well-controlled trials have been conducted for some SSRI(selective serotonin reuptake inhibitor) antidepressants, risperidone, and methylphenidate, and showed reduction of some target symptoms. Since the medications are not specific to autism and do not treat core symptoms of the disorder, their potential side effects should be carefully considered. Family education is necessary to give proper information on target symptoms, limitation of drug treatments, and risks.

  • PDF

자해 증상을 가진 발달장애아의 약물치료 (DRUG THERAPY FOR DEVELOPMENTAL DISORDER PATIENTS WITH SELF-MUTILATION)

  • 김봉석
    • Journal of the Korean Academy of Child and Adolescent Psychiatry
    • /
    • 제14권1호
    • /
    • pp.53-63
    • /
    • 2003
  • 자폐장애는 Leo Kanner가 처음 기술한 이래, 독립된 임상적 실체로 인식되어 왔다. 자폐장애의 원인은 불분명하며, 여러 가지 뇌구조와 기능 이상을 보인다. 자해는 저기능 자폐증 환자에서 나타나며, 만성화되지 않도록 조기 치료가 필요하다. 본 논문은 자폐증의 여러 증상에 사용되는 약물을 고찰하였으며, 특히 자해와 공격성에 대한 약물을 중점으로 고찰하였다. 세로토닌 재흡수차단제는 일차적 항공격 효과가 불분명하다. 도파민 차단약물은 공격성과 자기 손상을 감소시키는데 상당한 효과를 보이는데 부작용의 측면에서 리스페리돈이 가장 유효하다. 날트렉손은 아직까지 일관된 연구결과가 나오지 않았다. 클로니딘은 공격성 감소의 효과가 있다. 또한 리튬이 공격적 자기손상적 행동의 치료에 효과적이었다. 그리고 카바마제핀 등의 항경련제가 공격적 폭발적 행동에 효과적이었다. 앞으로 단일한 진단과 치료반응 측정을 통해 자해에 대한 약물치료가 보다 진보할 것이다.

  • PDF

항정신병약물로 유발된 고프로락틴혈증을 가진 조현병 환자의 삶의 질 (Quality of Life of Antipsychotic-Induced Hyperprolactinemia in Patients with Schizophrenia)

  • 우선진;진보현;원승희
    • 생물치료정신의학
    • /
    • 제24권3호
    • /
    • pp.218-229
    • /
    • 2018
  • Objectives : Antipsychotic-induced hyperprolactinemia causes physical symptoms, such as amenorrhea, galactorrhea, gynecomastia, sexual dysfunction, and bone density loss, as well as psychiatric symptoms, such as depression and cognitive impairments. This study aimed to clarify the associations among hyperprolactinemia caused by antipsychotics in patients with schizophrenia, psychiatric pathology, and psychosocial factors. Methods : Ninety-nine patients with schizophrenia in the psychiatry department of a university hospital were registered between 2015 and 2017. All participants were assessed using structured questionnaires to elucidate psychopathology, social function, quality of life, and hyperprolactinemia-related side effects. The standard levels for hyperprolactinemia were 24ng/mL for women and 20ng/mL for men. Results : The average prolactin levels were $73.45{\pm}49.37ng/mL$ in patients with hyperprolactinemia and $9.16{\pm}6.42ng/mL$ in those without hyperprolactinemia. The average prolactin level in women was significantly higher than that in men(p=0.04). Risperidone was most commonly administered in patients with hyperprolactinemia(58.1%, p<0.01), while aripiprazole was most commonly administered in those without hyperprolactinemia(44.7%, p<0.01). Patients with hyperprolactinemia had significantly higher Positive and Negative Syndrome Scale(p=0.03) and Patient Health Questionnaire-9(p=0.05) scores and had significantly lower Social and Occupational Functioning Assessment Scale(p=0.04) and Strauss-Carpenter Levels of Functioning Scale(p=0.03) scores than patients without hyperprolactinemia. There were no significant differences in side effects or quality of life between the two groups. Conclusion : These findings demonstrate that hyperprolactinemia confers negative effects on depression and social function, but does not directly affect the quality of life. These results suggest that patients with schizophrenia who take antipsychotics that increase prolactin or cause side effects of hyperprolactinemia need to be assessed and receive interventions for depression.

소아청소년 자폐 스펙트럼장애에서 메칠페니데이트 사용의 임상적 특징에 대한 후향적 분석 (Clinical Characteristics of Methylphenidate Use in Korean Children and Adolescents with Autism Spectrum Disorder : A Retrospective Study)

  • 박진박;이종일;진혜경;민혜지;황준원;김예니
    • Journal of the Korean Academy of Child and Adolescent Psychiatry
    • /
    • 제23권3호
    • /
    • pp.154-160
    • /
    • 2012
  • Objectives : The purpose of this study was to investigate clinical characteristics of children and adolescents with autism spectrum disorders (ASDs) using methylphenidate (MPH). Methods : Retrospective review of the charts of 79 children and adolescents with ASDs, who visited the Department of Child and Adolescent Psychiatry of Seoul National Hospital, from July 2010 to July 2011, was conducted. Changes in illness severity and improvement were measured using the Clinical Global Impression-Severity of illness (CGI-S) and Clinical Global Impression-Improvement (CGI-I) Scales. Results : We found that MPH was prescribed in 23 (29.1%) children and adolescents. Of the 23 patients on MPH, 4 patients (17.4%) were on MPH monotherapy and 18 patients (78.3%) were using risperidone concomitantly. MPH was prescribed primarily for symptoms of hyperactivity and impulsivity in ASDs patients. The mean dosage of MPH was $26.2{\pm}11.1$mg/day and mean duration of treatment was $31.9{\pm}28.7$ months. Mean CGI-S score improved significantly from baseline to endpoint (from $5.4{\pm}0.6$ to $4.1{\pm}0.9$ ; p<.01). MPH was reported to be effective in 17 patients (17/23, 73.9%), and 10 patients (10/23, 43.5%) reported side effects. Side effects included decreased appetite (4/23, 17.4%), tic (2/23, 8.6%), sleep disturbances (2/23, 8.6%), headache (1/23, 4.3%) and irritability (1/23, 4.3%). Conclusion : The results of this study demonstrate that MPH may be used effectively and safely in children and adolescents with ASDs with hyperactivity and impulsivity. Future controlled trials are needed to confirm these findings.

양극성 장애 환자에서 비정형 항정신병약물 치료 후에 나타나는 지연성 운동장애와 지연성 근긴장이상의 유병률 및 위험요인 (Tardive Dyskinesia and Tardive Dystonia with Second-Generation Antipsychotics in Bipolar Disorder Patients Unexposed to First-Generation Antipsychotics)

  • 이아람;김주현;백지현;김지선;최미지;윤세창;하규섭;홍경수
    • 생물정신의학
    • /
    • 제22권4호
    • /
    • pp.155-162
    • /
    • 2015
  • Objectives Second-generation antipsychotics (SGAs) are frequently used in the treatment of bipolar disorder. However, there is still no consensus on their risk of tardive movement syndromes especially for first-generation antipsychotics (FGAs)-naïve patients. This study aimed to investigate the prevalence and associated factors of SGAs-related tardive dyskinesia and tardive dystonia in patients with bipolar disorder, in a naturalistic out-patient clinical setting. Methods The authors assessed 78 non-elderly patients with bipolar (n = 71) or schizoaffective disorder (n = 7) who received SGAs with a combined use of mood stabilizers for more than three months without previous exposure to FGAs. Multiple direct assessments were performed and hospital records longer than one recent year describing any observed tardive movement symptoms were also reviewed. Results The prevalence rates of tardive dyskinesia and tardive dystonia were 7.7% and 6.4%, respectively. These patients were being treated with ziprasidone, risperidone, olanzapine, quetiapine, or paliperidone at the time of the onset of the movement symptoms. Tardive dyskinesia was mostly observed in the orolingual area, and tardive dystonia was most frequently detected in oromandibular area. A past history of acute dystonia was significantly associated with presence of both tardive movement syndromes. Conclusions Our findings suggest that SGAs-related tardive movement syndromes occur in a substantial portion of bipolar disorder patients. Acute dystonia, a reported risk factor of tardive movement syndromes in the era of FGAs is confirmed as a risk factor of both tardive dyskinesia and tardive dystonia that were induced-by SGAs.